Silence Therapeutics (SLN.US): The 2024 Q1 financial report achieved revenue of US$15.734 million, previous value of US$13.815 million; earnings per share were -0.05 USD, prior value of -0.12 USD.
Silence Therapeutics (SLN.US): The 2024 Q1 financial report achieved revenue of US$15.734 million, previous value of US$13.815 million; earnings per share were -0.05 USD, prior value of -0.12 USD.
Silence Therapeutics Posts Reduced Q1 Losses
6-K: Report of foreign private issuer (related to financial reporting)
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading
European equities traded in the US as American depositary receipts were trending moderately lower late Thursday morning, declining 0.61% to 1,426.72 on the S&P Europe Select ADR Index. From continenta
Silence Therapeutics Q1 Collaboration Revenue £12.4M, Up £1M YoY; Cash Position £152.8M
Silence Therapeutics Q1 Collaboration Revenue £12.4M, Up £1M YoY; Cash Position £152.8M
Silence Therapeutics 1Q Rev GBP12.4M >SLN
Silence Therapeutics 1Q Rev GBP12.4M >SLN
Press Release: Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress
Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress LONDON--(BUSINESS WIRE)--May 16, 2024-- Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Wednesday Trading
European equities traded in the US as American depositary receipts were trending slightly higher Wednesday morning, rising 0.10% to 1,427.23 on the S&P Europe Select ADR Index. From continental Europe
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher
European equities traded in the US as American depositary receipts kicked off the week higher in Monday morning, rising 0.62% to 1,421.16 on the S&P Europe Select ADR Index. From continental Europe, t
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
European equities traded in the US as American depositary receipts rose late Thursday morning, gaining 0.35% to 1,403.4 on the S&P Europe Select ADR Index. From continental Europe, the gainers were le
Silence Therapeutics Files to Sell 5.71M American Depositary Shares for Holders
Silence Therapeutics Announces Board Change
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference
Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered
Silence Therapeutics Announces Retirement of Alistair Gray From Board of Directors
Silence Therapeutics plc (NASDAQ:SLN) ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered
Beyond The Numbers: 7 Analysts Discuss Silence Therapeutics Stock
7 analysts have expressed a variety of opinions on Silence Therapeutics (NASDAQ:SLN) over the past quarter, offering a diverse set of opinions from bullish to bearish.The table below summarizes their
Silence Therapeutics Is Maintained at Overweight by Morgan Stanley
Silence Therapeutics Is Maintained at Overweight by Morgan Stanley
Damo: Maintaining the Silence Therapeutics (SLN.US) rating, adjusted from an increase holdings to an increase rating, and the target price was adjusted from $45.00 to $45.00.
Damo: Maintaining the Silence Therapeutics (SLN.US) rating, adjusted from an increase holdings to an increase rating, and the target price was adjusted from $45.00 to $45.00.
Morgan Stanley Maintains Overweight on Silence Therapeutics, Maintains $45 Price Target
Morgan Stanley analyst Michael Ulz maintains Silence Therapeutics (NASDAQ:SLN) with a Overweight and maintains $45 price target.
Silence Therapeutics Plc's (NASDAQ:SLN) Market Cap Touched US$1.1b Last Week, Benefiting Both Retail Investors Who Own 27% as Well as Institutions
Key Insights Silence Therapeutics' significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public 54% of the business is held by the top
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down
European equities traded in the US as American depositary receipts were trending higher Friday morning, rising 0.46% to 1,330.20 on the S&P Europe Select ADR Index. Despite the gain, the index remains
No Data